These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 15903057)

  • 21. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
    Mudaliar S; Henry RR
    Annu Rev Med; 2001; 52():239-57. PubMed ID: 11160777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical efficacy of metformin against insulin resistance parameters: sinking the iceberg.
    Zimmet P; Collier G
    Drugs; 1999; 58 Suppl 1():21-8; discussion 75-82. PubMed ID: 10576521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sitagliptin: a novel drug for the treatment of type 2 diabetes.
    Choy M; Lam S
    Cardiol Rev; 2007; 15(5):264-71. PubMed ID: 17700385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of pioglitazone add-on to gliclazide and metformin on glycemic control in patients with type 2 diabetes.
    Al-Azzam SI; Alomari M; Khader YS; Almahasneh FA; Muflih SM; Altawalbeh S
    Endocr Res; 2012; 37(1):7-11. PubMed ID: 21977974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
    DeFronzo RA; Burant CF; Fleck P; Wilson C; Mekki Q; Pratley RE
    J Clin Endocrinol Metab; 2012 May; 97(5):1615-22. PubMed ID: 22419732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
    Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study.
    Matthews DR; Charbonnel BH; Hanefeld M; Brunetti P; Schernthaner G
    Diabetes Metab Res Rev; 2005; 21(2):167-74. PubMed ID: 15386821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus.
    Strowig SM; Raskin P
    Diabetes Obes Metab; 2005 Nov; 7(6):633-41. PubMed ID: 16219007
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prevention and treatment for development and progression of diabetic macroangiopathy with pioglitazone and metformin].
    Tamura H; Mokuno H; Daita H
    Nihon Rinsho; 2006 Nov; 64(11):2119-25. PubMed ID: 17087306
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pioglitazone protects the type-2-diabetes patient from myocardial infarction and stroke].
    MMW Fortschr Med; 2007 Aug; 149(31-32):52-3. PubMed ID: 17849787
    [No Abstract]   [Full Text] [Related]  

  • 32. [Glitazones clinical data: an update].
    Guerci B
    Ann Endocrinol (Paris); 2005 Apr; 66(2 Pt 2):1S45-58. PubMed ID: 15959404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Free radical scavenging activity of sulfonylureas: a clinical assessment of the effectiveness of gliclazide].
    Jennings PE; Belch JJ
    Ter Arkh; 2001; 73(4):27-31. PubMed ID: 11494442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes.
    Raskin P
    Diabetes Metab Res Rev; 2008; 24(1):3-13. PubMed ID: 17968971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New drugs and clinical trials in diabetes and hypertension.
    Nilsson P
    Exp Clin Endocrinol Diabetes; 1997; 105 Suppl 2():64-9. PubMed ID: 9288549
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin.
    Derosa G; Salvadeo SA; D'Angelo A; Fogari E; Ragonesi PD; Ciccarelli L; Piccinni MN; Ferrari I; Gravina A; Maffioli P; Cicero AF
    Arch Med Res; 2008 May; 39(4):412-9. PubMed ID: 18375253
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Too positive comment on glitazones].
    Lindberg M
    Ugeskr Laeger; 2007 Feb; 169(8):733; author reply 733. PubMed ID: 17338040
    [No Abstract]   [Full Text] [Related]  

  • 38. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.
    Nesto RW; Bell D; Bonow RO; Fonseca V; Grundy SM; Horton ES; Le Winter M; Porte D; Semenkovich CF; Smith S; Young LH; Kahn R; ;
    Circulation; 2003 Dec; 108(23):2941-8. PubMed ID: 14662691
    [No Abstract]   [Full Text] [Related]  

  • 39. The current role of thiazolidinediones in diabetes management.
    Rizos CV; Kei A; Elisaf MS
    Arch Toxicol; 2016 Aug; 90(8):1861-81. PubMed ID: 27165418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Guideline-conformity of initiation with oral hypoglycemic treatment for patients with newly therapy-dependent type 2 diabetes mellitus in Austria.
    Winkelmayer WC; Stedman MR; Pogantsch M; Wieninger P; Bucsics A; Asslaber M; Bauer R; Burkhardt T; Schautzer A; Brookhart MA;
    Pharmacoepidemiol Drug Saf; 2011 Jan; 20(1):57-65. PubMed ID: 21182153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.